Phase 2 Trials Begin For Promising New Dry Eye Disease Treatment From OKYO Pharma
  • 11 months ago
OKYO Pharma is a biotechnology company focused on the treatment of ocular diseases. OKYO is currently developing OK-101 to treat dry eye disease, which is a currently underserved and untreated condition affecting millions of people in the U.S. According to the company, the addressable market exceeds $5 billion.